Multaq 400 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26F9EAS
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,289
Award facts
- Contract value 100% obligated
- $14,288.52 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order to Amerisourcebergen Drug Corp on January 30, 2026, for the supply of Multaq 400 mg tablets (60-count packaging) under a firm fixed-price contract valued at $14,288.52, with completion targeted for February 2, 2026. This non-compete, non-set-aside award represents a task order issued against the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The place of performance is listed as Conshohocken, Pennsylvania, where Amerisourcebergen maintains its corporate headquarters. Multaq (dronedarone) is an antiarrhythmic medication used in the treatment of atrial fibrillation, reflecting the pharmaceutical distributor's ongoing role in supplying specialty medications to support military healthcare programs.
Amerisourcebergen Drug Corp operates as a subsidiary of parent company Cencora, Inc. (doing business as Amerisourcebergen), one of the nation's largest pharmaceutical distributors. The parent entity maintains a significant $999,999,999.00 IDC with the DLA through December 31, 2031, enabling the supply of a comprehensive range of medications, medical devices, vaccines, and healthcare commodities across multiple therapeutic domains to military treatment facilities and veterans' healthcare systems worldwide. Amerisourcebergen's consistent success in securing federal pharmaceutical contracts, including this delivery order, demonstrates the company's established capability to meet government procurement requirements through open competition and its critical role within the defense medical supply chain.
Quick answers
Who was awarded contract SPE2DR26F9EAS?
SPE2DR26F9EAS was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 30, 2026.
How much is contract SPE2DR26F9EAS worth?
The government has obligated $14,289 on SPE2DR26F9EAS.
Is contract SPE2DR26F9EAS an order under another contract?
Yes. SPE2DR26F9EAS is a delivery order under SPE2DR25D1017, an indefinite delivery contract.
Was contract SPE2DR26F9EAS competed?
The extent of competition for SPE2DR26F9EAS was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award